Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | HCAR2 | Q8TDS4 | 4/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1233899 | 0.84 | HCAR2 (0.64) | KMT2ANPSR1L3MBTL1POLBHCAR2 | |
| SCHEMBL7705757 | 0.83 | HCAR2 (0.59) | KMT2ANPSR1L3MBTL1POLBHCAR2 | |
| SCHEMBL4002119 | 0.81 | KMT2A (0.50) | KMT2ANPSR1L3MBTL1POLBTP53 | |
| SCHEMBL20468132 | 0.81 | HCAR2 (0.53) | KMT2ANPSR1L3MBTL1POLBHCAR2 | |
| SCHEMBL21607841 | 0.81 | HCAR2 (0.66) | KMT2ANPSR1L3MBTL1POLBHCAR2 | |
| SCHEMBL1259028 | 0.81 | HCAR2 (0.66) | KMT2ANPSR1L3MBTL1POLBHCAR2 | |
| SCHEMBL11093186 | 0.81 | KMT2A (0.50) | KMT2ANPSR1L3MBTL1POLBHCAR2 | |
| SCHEMBL20525148 | 0.81 | KMT2A (0.50) | KMT2ANPSR1L3MBTL1POLBHCAR2 | |
| SCHEMBL21810968 | 0.81 | KMT2A (0.48) | KMT2ANPSR1L3MBTL1POLBHCAR2 | |
| SCHEMBL1232913 | 0.81 | POLB (0.41) | KMT2ANPSR1L3MBTL1POLBHCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010043633-A1 | 2H-PYRAZOLO [4,3-D]PYRIMIDIN-5-AMINE DERIVATIVES AS H4 HISTAMINE RECEPTOR ANTAGONISTS FOR THE TREATMENT OF ALLERGIC, IMMUNOLOGICAL AND INFLAMMATORY DISEASES | PALAU PHARMA, S. A. (ES) | 2010-04-22 | — | — | WO | disclosed |